Immatics Gross Profit from 2010 to 2025

IMTXW Stock

USD 0.02 0.01 31.91%

Immatics Biotechnologies Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit immatics biotechnologies GmbH makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2018-03-31

Previous Quarter

18.7 M

Current Value

50.6 M

Quarterly Volatility

23.6 M

Covid

Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 15.7 M or Interest Income of 16.7 M, as well as many indicators such as Price To Sales Ratio of 15.53, Dividend Yield of 0.0 or PTB Ratio of 3.22. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.

Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of immatics biotechnologies GmbH over the last few years. Gross profit is a required income statement account that reflects total revenue of immatics biotechnologies GmbH minus its cost of goods sold. It is profit before Immatics Biotechnologies operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Immatics Biotechnologies' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (23.99 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Immatics Gross Profit Regression Statistics

	Arithmetic Mean	(11,778,614)
	Geometric Mean	11,444,399
	Coefficient Of Variation	(289.47)
	Mean Deviation	27,221,018
	Median	3,770,000
	Standard Deviation	34,096,044
	Sample Variance	1162.5T
	Range	130.7M
	R-Value	(0.52)
	Mean Square Error	903T
	R-Squared	0.28
	Significance	0.04
	Slope	(3,755,977)
	Total Sum of Squares	17438.1T

Immatics Gross Profit History

	2025	-55.3 M
	2024	-58.2 M
	2023	-64.7 M
	2022	66.1 M
	2021	-52.8 M
	2020	-35.8 M
	2019	-21.6 M

Other Fundumenentals of Immatics Biotechnologies

Gross Profit Margin

Immatics Biotechnologies Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.93	0.85	-0.81	-0.83	0.63	0.59	0.91	0.88	0.93	1.0	-0.67	0.99	0.07	0.91	-0.67
Total Stockholder Equity	0.93		0.67	-0.88	-0.91	0.4	0.41	0.96	0.71	1.0	0.93	-0.81	0.94	0.01	0.87	-0.81
Current Deferred Revenue	0.85	0.67		-0.55	-0.52	0.94	0.8	0.76	1.0	0.67	0.84	-0.26	0.78	0.37	0.77	-0.26
Net Debt	-0.81	-0.88	-0.55		0.88	-0.28	-0.46	-0.74	-0.59	-0.88	-0.82	0.83	-0.84	0.35	-0.61	0.83
Retained Earnings	-0.83	-0.91	-0.52	0.88		-0.21	-0.15	-0.8	-0.55	-0.91	-0.83	0.94	-0.83	0.06	-0.82	0.94
Accounts Payable	0.63	0.4	0.94	-0.28	-0.21		0.84	0.54	0.92	0.4	0.61	0.07	0.53	0.48	0.54	0.07
Net Receivables	0.59	0.41	0.8	-0.46	-0.15	0.84		0.47	0.8	0.41	0.59	0.04	0.58	-0.02	0.31	0.04
Short Term Investments	0.91	0.96	0.76	-0.74	-0.8	0.54	0.47		0.78	0.96	0.91	-0.63	0.9	0.25	0.91	-0.63
Total Liab	0.88	0.71	1.0	-0.59	-0.55	0.92	0.8	0.78		0.71	0.86	-0.31	0.81	0.33	0.78	-0.31
Net Invested Capital	0.93	1.0	0.67	-0.88	-0.91	0.4	0.41	0.96	0.71		0.93	-0.81	0.94	0.01	0.87	-0.81
Total Current Assets	1.0	0.93	0.84	-0.82	-0.83	0.61	0.59	0.91	0.86	0.93		-0.67	0.99	0.05	0.9	-0.67
Capital Stock	-0.67	-0.81	-0.26	0.83	0.94	0.07	0.04	-0.63	-0.31	-0.81	-0.67		-0.69	0.28	-0.65	1.0
Net Working Capital	0.99	0.94	0.78	-0.84	-0.83	0.53	0.58	0.9	0.81	0.94	0.99	-0.69		-0.04	0.87	-0.69
Short Term Debt	0.07	0.01	0.37	0.35	0.06	0.48	-0.02	0.25	0.33	0.01	0.05	0.28	-0.04		0.38	0.28
Intangible Assets	0.91	0.87	0.77	-0.61	-0.82	0.54	0.31	0.91	0.78	0.87	0.9	-0.65	0.87	0.38		-0.65
Common Stock	-0.67	-0.81	-0.26	0.83	0.94	0.07	0.04	-0.63	-0.31	-0.81	-0.67	1.0	-0.69	0.28	-0.65

Click cells to compare fundamentals

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-58.2 M	-55.3 M
Gross Profit Margin	(1.08)	(1.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC